Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 14q12 Microdeletion Syndrome C4305240
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 14q12 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
14q12 Microdeletion Syndrome C4305240
A rare chromosomal condition where a segment of chromosome 14 is missing. It may cause developmental delays and other health concerns. Treatment is supportive and individualized.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
14q12 Microdeletion Syndrome C4305240
0-1
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
14q12 Microdeletion Syndrome C4305240
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
14q12 Microdeletion Syndrome C4305240
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
14q12 Microdeletion Syndrome C4305240
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
14q12 Microdeletion Syndrome C4305240
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
14q12 Microdeletion Syndrome C4305240
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 14q12-microdeletion-syndrome-C4305240 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 14q12 Microdeletion Syndrome C4305240 | Discriminating power |
|---|---|---|---|
| Pubertal development | Source data describe absent puberty; exact pattern varies. | Pubertal effects are not established by the supplied description. | Moderate |
| Blood pressure | High blood pressure is described and needs clinical confirmation. | Hypertension is not a stated feature in the source data. | Moderate |
| Development | Developmental delay is not a stated core feature. | Developmental delay and other concerns may occur. | High |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Ambiguous genitalia with absent puberty
These endocrine features match the supplied description.
Moderate
Hypertension with suspected steroid disorder
High blood pressure is described, but testing must confirm the mechanism.
Moderate
Need for lifelong hormone replacement
The source states replacement is required; regimen is individualized.
High
Choose 14q12 Microdeletion Syndrome C4305240 when
Early developmental delay
Developmental delay is the main stated clinical concern.
Moderate
Suspected chromosomal microdeletion
The condition is defined by missing material from chromosome 14.
High
Need for supportive, individualized care
No disease-specific treatment is established in the source.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 14q12 Microdeletion Syndrome C4305240 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal steroid production may be found; cutoffs are not specified here. | No characteristic steroid abnormality is established. | An abnormal result supports endocrine evaluation but is not itself a diagnosis. |
| Chromosomal microarray | Not expected to define this enzyme disorder. | May identify a 14q12 microdeletion when clinically indicated. | Genetic confirmation requires specialist interpretation. |
| Blood pressure measurement | Hypertension may be present. | No specific blood-pressure pattern is established. | Blood pressure is a finding, not a diagnostic test. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine condition; exact outcomes are not established here.
- Factors
- Hormone management, blood pressure, and individual findings may influence course.
14q12 Microdeletion Syndrome C4305240
- Outcome
- Chronic congenital condition with variable developmental impact.
- Factors
- Deletion findings, developmental needs, and associated health issues may influence course.
Time frame: Both are chronic; onset is described from childhood, with the microdeletion often recognized in infancy.
Prognosis should be individualized because comparative outcome data are not supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related effects | High blood pressure is described and may need monitoring. Not established from the supplied data. Complications depend on individual findings and care. |
| Pubertal or reproductive effects | Absent puberty and genital ambiguity are described. Not established from the supplied data. Counseling should be individualized. |
| Developmental concerns | Not a stated core feature. Developmental delay and other health concerns may occur. Supportive services are tailored to assessed needs. |
Patient education highlights
- HighDifferent causes
One affects steroid production; the other involves missing chromosome 14 material.
- HighSpecialist follow-up
Endocrine or genetics clinicians should interpret tests and guide care.
- MediumLong-term care
Hormone replacement or supportive therapy may be lifelong and individualized.